Covered recipient · General Payments record
ANDREW TUCKER KUYKENDALL
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$66,627.49
60 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $53,892.50 | 22 |
| Travel and Lodging | $7,717.47 | 19 |
| Honoraria | $3,953.52 | 3 |
| Food and Beverage | $1,064.00 | 16 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $18,177.50 | 12 |
| Incyte Corporation | $18,158.31 | 22 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18,147.44 | 14 |
| Karyopharm Therapeutics Inc. | $6,552.59 | 7 |
| Blueprint Medicines Corporation | $2,948.00 | 1 |
| Geron Corporation | $2,643.65 | 4 |
Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANDREW TUCKER KUYKENDALL
NPI 1154697738 · CMS profile ID 1381292
Allopathic & Osteopathic Physicians / Internal Medicine
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANDREW TUCKER KUYKENDALL, NPI 1154697738, CMS profile ID 1381292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ANDREW TUCKER KUYKENDALL, NPI 1154697738, CMS profile ID 1381292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ANDREW TUCKER KUYKENDALL, NPI 1154697738, CMS profile ID 1381292, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1154697738?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
60 matching records · $66,627.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–60 of 60.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $567.04 | 06/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224100867 | CMS |
| Blueprint Medicines Corporation | $2,948.00 | 06/13/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235820396 | CMS |
| Geron Corporation | $102.32 | 05/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238890442 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $127.21 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223943460 | CMS |
| Karyopharm Therapeutics Inc. | $407.50 | 05/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1246642221 | CMS |
| Merck Sharp & Dohme LLC | $1,220.00 | 05/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238008470 | CMS |
| Geron Corporation | $27.47 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238890440 | CMS |
| Merck Sharp & Dohme LLC | $2,440.00 | 04/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238036082 | CMS |
| Merck Sharp & Dohme LLC | $3,965.00 | 01/15/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238008480 | CMS |
| Incyte Corporation | $3,425.00 | 01/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1226067386 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $142.60 | 1 |
| PY2025 | Principal investigator | $1,047,617.31 | 155 |
| PY2024 | Principal investigator | $643,255.26 | 47 |
| PY2023 | Principal investigator | $307,535.37 | 21 |
| PY2022 | Principal investigator | $343,252.74 | 41 |
| PY2021 | Principal investigator | $30,508.11 | 11 |
| PY2020 | Principal investigator | $236,226.45 | 47 |
| PY2019 | Principal investigator | $59,790.22 | 49 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
156 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $3,312.00 | 12/29/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175392910 |
| Principal investigator 1 | Janssen Research & Development, LLC | $504.00 | 12/26/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393660 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $636.00 | 12/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy | No dispute reported | 06/30/2026 | 1226146216 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76,530.50 | 12/22/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393752 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $530.00 | 12/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy | No dispute reported | 06/30/2026 | 1226146212 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 12/15/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175394088 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 12/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1240476629 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,352.00 | 12/01/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393970 |
| Principal investigator 1 | Janssen Research & Development, LLC | $636.00 | 11/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 11/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393910 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,327.00 | 11/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175394019 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,618.40 | 11/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) | No dispute reported | 06/30/2026 | 1226146209 |
| Principal investigator 1 | Janssen Research & Development, LLC | $145,801.40 | 11/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,022.00 | 11/03/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393010 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893971 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893975 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893979 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893983 |
| Principal investigator 1 | Geron Corporation | $266.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893987 |
| Principal investigator 1 | Geron Corporation | $544.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893991 |
| Principal investigator 1 | Geron Corporation | $3,156.83 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893995 |
| Principal investigator 1 | Geron Corporation | $3,865.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893999 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894003 |
| Principal investigator 1 | Geron Corporation | $3,156.83 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894007 |
| Principal investigator 1 | Geron Corporation | $136.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894011 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894016 |
| Principal investigator 1 | Geron Corporation | $3,552.18 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894021 |
| Principal investigator 1 | Geron Corporation | $266.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894026 |
| Principal investigator 1 | Geron Corporation | $204.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894030 |
| Principal investigator 1 | Geron Corporation | $3,243.74 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894034 |
| Principal investigator 1 | Geron Corporation | $266.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894037 |
| Principal investigator 1 | Geron Corporation | $544.00 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894041 |
| Principal investigator 1 | Geron Corporation | $3,552.18 | 10/29/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894046 |
| Principal investigator 1 | Janssen Research & Development, LLC | $64,093.08 | 10/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393964 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,725.00 | 10/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) | No dispute reported | 06/30/2026 | 1226146201 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $61,890.58 | 10/08/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | No dispute reported | 06/30/2026 | 1190314079 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,019.60 | 10/02/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) | No dispute reported | 06/30/2026 | 1226146205 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,638.00 | 09/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) | No dispute reported | 06/30/2026 | 1226146198 |
| Principal investigator 1 | Geron Corporation | $204.00 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893943 |
| Principal investigator 1 | Geron Corporation | $136.00 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893946 |
| Principal investigator 1 | Geron Corporation | $3,552.18 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893951 |
| Principal investigator 1 | Geron Corporation | $544.00 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893954 |
| Principal investigator 1 | Geron Corporation | $68.00 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893959 |
| Principal investigator 1 | Geron Corporation | $70.72 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893964 |
| Principal investigator 1 | Geron Corporation | $3,156.83 | 08/27/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893967 |
| Principal investigator 1 | Janssen Research & Development, LLC | $451.00 | 08/25/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393302 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,218.00 | 08/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393734 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,455.49 | 08/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393929 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $495.00 | 08/07/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN) | No dispute reported | 06/30/2026 | 1226146196 |
| Recipient | Novartis Pharmaceuticals Corporation | $142.60 | 08/05/2025 | Covered Recipient Physician | CDAK539A12301 | No dispute reported | 06/30/2026 | 1190292616 |
| Principal investigator 1 | Janssen Research & Development, LLC | $662.00 | 08/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175394065 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893783 |
| Principal investigator 1 | Geron Corporation | $5,614.76 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893787 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893791 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893799 |
| Principal investigator 1 | Geron Corporation | $266.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893803 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893808 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893812 |
| Principal investigator 1 | Geron Corporation | $3,156.83 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893816 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893820 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893825 |
| Principal investigator 1 | Geron Corporation | $70.72 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893829 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893834 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893838 |
| Principal investigator 1 | Geron Corporation | $266.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893842 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893847 |
| Principal investigator 1 | Geron Corporation | $5,614.76 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893851 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893855 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893857 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893862 |
| Principal investigator 1 | Geron Corporation | $544.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893866 |
| Principal investigator 1 | Geron Corporation | $266.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893870 |
| Principal investigator 1 | Geron Corporation | $70.72 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893874 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893878 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893883 |
| Principal investigator 1 | Geron Corporation | $70.72 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893887 |
| Principal investigator 1 | Geron Corporation | $70.72 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893891 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893895 |
| Principal investigator 1 | Geron Corporation | $204.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893900 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893903 |
| Principal investigator 1 | Geron Corporation | $3,715.38 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893906 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893909 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893913 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893915 |
| Principal investigator 1 | Geron Corporation | $136.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893919 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893923 |
| Principal investigator 1 | Geron Corporation | $266.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893927 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893931 |
| Principal investigator 1 | Geron Corporation | $141.44 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893935 |
| Principal investigator 1 | Geron Corporation | $252.00 | 07/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $687.00 | 07/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393290 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,008.00 | 07/11/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175392876 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,811.73 | 07/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,365.91 | 06/30/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393185 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,295.68 | 06/26/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1192101495 |
| Principal investigator 1 | Blueprint Medicines Corporation | $1,627.00 | 06/18/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ava + Aza Combo Trial | No dispute reported | 06/30/2026 | 1235785591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,432.45 | 06/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393584 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,692.00 | 06/06/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175392921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,996.25 | 06/06/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393975 |
| Principal investigator 1 | Blueprint Medicines Corporation | $7,946.04 | 06/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy | No dispute reported | 06/30/2026 | 1235785503 |
| Principal investigator 1 | Blueprint Medicines Corporation | $1,618.40 | 06/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ava + Aza Combo Trial | No dispute reported | 06/30/2026 | 1235785587 |
| Principal investigator 1 | Blueprint Medicines Corporation | $673.20 | 05/23/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ava + Aza Combo Trial | No dispute reported | 06/30/2026 | 1235785583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,458.54 | 05/05/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393355 |
| Principal investigator 1 | Geron Corporation | $500.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893713 |
| Principal investigator 1 | Geron Corporation | $1,224.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893717 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893721 |
| Principal investigator 1 | Geron Corporation | $2,380.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893725 |
| Principal investigator 1 | Geron Corporation | $3,513.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893727 |
| Principal investigator 1 | Geron Corporation | $3,228.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893731 |
| Principal investigator 1 | Geron Corporation | $3,978.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893737 |
| Principal investigator 1 | Geron Corporation | $141.44 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893742 |
| Principal investigator 1 | Geron Corporation | $1,980.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893747 |
| Principal investigator 1 | Geron Corporation | $252.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893755 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893759 |
| Principal investigator 1 | Geron Corporation | $266.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893763 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893768 |
| Principal investigator 1 | Geron Corporation | $252.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893772 |
| Principal investigator 1 | Geron Corporation | $266.00 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893776 |
| Principal investigator 1 | Geron Corporation | $141.44 | 04/25/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238893780 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.00 | 04/21/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175394031 |
| Principal investigator 1 | Blueprint Medicines Corporation | $2,807.00 | 04/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy | No dispute reported | 06/30/2026 | 1235785475 |
| Principal investigator 1 | Blueprint Medicines Corporation | $264.00 | 04/04/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy | No dispute reported | 06/30/2026 | 1235785471 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $93,843.14 | 04/02/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | No dispute reported | 06/30/2026 | 1190296552 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,052.00 | 03/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $266.00 | 03/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,847.00 | 03/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393723 |
| Principal investigator 1 | Janssen Research & Development, LLC | $266.00 | 03/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175394059 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,366.40 | 03/10/2025 | Covered Recipient Teaching Hospital MOFFITT CANCER CENTER | EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1192101503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,542.92 | 03/03/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393261 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894361 |
| Principal investigator 1 | Geron Corporation | $3,118.89 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894365 |
| Principal investigator 1 | Geron Corporation | $2,672.40 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894369 |
| Principal investigator 1 | Geron Corporation | $266.00 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894372 |
| Principal investigator 1 | Geron Corporation | $5,614.76 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894376 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894380 |
| Principal investigator 1 | Geron Corporation | $3,711.44 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894384 |
| Principal investigator 1 | Geron Corporation | $2,884.56 | 02/28/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894389 |
| Principal investigator 1 | Blueprint Medicines Corporation | $3,110.00 | 02/24/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ava + Aza Combo Trial | No dispute reported | 06/30/2026 | 1235785579 |
| Principal investigator 1 | Geron Corporation | $3,552.18 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894221 |
| Principal investigator 1 | Geron Corporation | $252.00 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894225 |
| Principal investigator 1 | Geron Corporation | $636.00 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894228 |
| Principal investigator 1 | Geron Corporation | $70.72 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894231 |
| Principal investigator 1 | Geron Corporation | $204.00 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894235 |
| Principal investigator 1 | Geron Corporation | $136.00 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894240 |
| Principal investigator 1 | Geron Corporation | $3,156.83 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894244 |
| Principal investigator 1 | Geron Corporation | $204.00 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894248 |
| Principal investigator 1 | Geron Corporation | $544.00 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894252 |
| Principal investigator 1 | Geron Corporation | $141.44 | 02/21/2025 | Non-covered Recipient Entity MOFFITT CANCER CENTER H LEE MOFFITT CANCER CENTER | An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Myelofibrosis | No dispute reported | 06/30/2026 | 1238894256 |
| Principal investigator 1 | Janssen Research & Development, LLC | $982.00 | 02/17/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175394050 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $53,983.12 | 02/14/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | No dispute reported | 06/30/2026 | 1190295725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,981.65 | 02/10/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393418 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,178.00 | 01/27/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175392885 |
| Principal investigator 1 | Blueprint Medicines Corporation | $768.00 | 01/16/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | Ava + Aza Combo Trial | No dispute reported | 06/30/2026 | 1235785575 |
| Principal investigator 1 | Janssen Research & Development, LLC | $266.00 | 01/09/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175393081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,131.17 | 01/06/2025 | Covered Recipient Teaching Hospital Moffitt Cancer Center | A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, ConcurrentlyAdministered with Ipilimumab for the Treatment of Myeloproliferative Neoplasms | No dispute reported | 06/30/2026 | 1175392943 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $106,097.23 | 01/02/2025 | Non-covered Recipient Entity H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients | No dispute reported | 06/30/2026 | 1190301191 |